- HK$13.06bn
- HK$18.66bn
- CNY6.06bn
- 24
- 54
- 87
- 58
Annual income statement for Luye Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5,540 | 5,200 | 5,982 | 6,143 | 6,061 |
| Cost of Revenue | |||||
| Gross Profit | 3,991 | 3,397 | 4,141 | 4,204 | 4,044 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4,175 | 4,876 | 4,841 | 4,768 | 4,660 |
| Operating Profit | 1,364 | 324 | 1,141 | 1,375 | 1,402 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 942 | -74.6 | 670 | 700 | 839 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 703 | -145 | 583 | 539 | 645 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 707 | -134 | 605 | 533 | 472 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 707 | -134 | 605 | 533 | 472 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.221 | 0.01 | 0.191 | 0.144 | 0.126 |
| Dividends per Share |